What is Polyendocrine Metabolic Ovarian Syndrome?

​

Polyendocrine Metabolic Ovarian Syndrome, formerly called Polycystic Ovary Syndrome (PCOS), is a complex endocrinopathy and metabolic disorder that begins around puberty. Genetic and environmental factors are thought to be the main causes. There are a few factors associated with this condition:

​

Insulin Resistance - intrinsic insulin resistance independent of body mass index (BMI) is a common finding. High circulating insulin acts synergistically with luteinizing hormone (LH) on ovarian cells to increase androgen production. Furthermore, hyperinsulinemia suppresses hepatic synthesis of Sex Hormone-Binding Globulin (SHBG), which increases the amount of free, active androgens.

 

Gonadotropin Dysregulation - Altered hypothalamic GnRH secretion can favor LH secretion and contribute to increased ovarian androgen production and impaired normal follicular development.

 

Chronic Low-Grade Inflammation - elevated inflammatory markers further exacerbate insulin resistance and stimulate ovarian androgen production.

 

Diagnostics

​

Diagnosis requires exclusion of other conditions that can cause similar symptoms, such as thyroid disease, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, Cushing syndrome, and androgen-secreting disorders.

​

In adults, diagnosis requires at least 2 of the following 3 criteria:

​

• Ovulatory Dysfunction — Irregular, infrequent, or absent menstrual cycles. In adults, irregular cycles generally include cycles <21 or >35 days apart or fewer than 8 cycles per year.

• Clinical and/or Biochemical Hyperandrogenism

  • Clinical: Hirsutism (excess hair growth in male pattern), severe acne and oily skin, male-pattern hair loss/thinning, increased muscle mass...

  • Biochemical: Elevated total and/or free testosterone

• Polycystic Ovarian Morphology (PCOM) — May be identified in adults by pelvic ultrasound or with serum anti-Müllerian hormone (AMH) using an appropriate assay-specific threshold.

 

If an adult already has both irregular menstrual cycles/ovulatory dysfunction and hyperandrogenism, ultrasound or AMH is not necessary to establish the diagnosis. Ultrasound and AMH generally should not both be ordered solely to establish polycystic ovarian morphology.

​

In adolescents diagnosis is more conservative because irregular menstrual cycles, acne, and multifollicular ovaries can be normal during puberty. Pelvic ultrasound and AMH are not recommended for diagnosing PMOS in adolescents because they lack adequate specificity during this stage of reproductive development.

​

 

Clinical Presentation & Complications

​

Reproductive & Gynecologic

• Oligomenorrhea or amenorrhea (infrequent or absent menstrual periods)

• Anovulatory infertility

• Increased risk of Endometrial Hyperplasia & Endometrial Cancer (due to chronic unopposed estrogen stimulating the uterine lining without progesterone withdrawal)

Metabolic & Endocrine

• Type 2 Diabetes Mellitus

• Dyslipidemia (high triglycerides, low HDL, high LDL)

• Metabolic Syndrome and Central/Visceral Adiposity

• Non-Alcoholic Fatty Liver Disease (NAFLD / MASH)

Cardiovascular

• Essential Hypertension

• Endothelial dysfunction and early vascular stiffness

• Increased long-term risk of cardiovascular disease

Dermatologic

• Hirsutism (excessive male-pattern hair growth on the face, chest, lower abdomen, inner thighs)

• Severe or cystic acne

• Acanthosis nigricans (hyperpigmented, velvety skin plaques in body folds indicating insulin resistance)

Psychological & Sleep

• Anxiety, major depressive disorder, and body image dissatisfaction

• High prevalence of Obstructive Sleep Apnea (OSA)

 

Management

​

1. Lifestyle Interventions (First-Line Foundation)

• Dietary Modification: Low-glycemic index (GI) diet, anti-inflammatory nutrition, and carbohydrate distribution to stabilize postprandial glucose and insulin spikes.

• Exercise: Combined aerobic and resistance training to enhance skeletal muscle insulin sensitivity, independent of weight loss.

• Weight Management: A modest weight loss of 5–10% of total body weight can restore ovulatory menstrual cycles, improve free androgen levels, and enhance fertility response.

2. Pharmacotherapy for Non-Fertility Goals

• Combined Oral Contraceptives (COCs): First-line medical therapy for cycle regulation and hyperandrogenism in patients not seeking pregnancy. Progestin suppresses LH, while estrogen increases hepatic SHBG production, binding free testosterone.

• Insulin Sensitizers (Metformin): Improves peripheral insulin sensitivity, lowers circulating fasting insulin, reduces hepatic glucose output, and aids in modest weight reduction and metabolic risk management.

• Anti-Androgens (Spironolactone, Finasteride): Added if hyperandrogenism symptoms (hirsutism/acne) persist after 6 months of COC therapy. (Note: Strict contraception is mandatory due to risk of teratogenicity/feminization of a male fetus).

3. Management of Anovulatory Infertility

• Letrozole (Aromatase Inhibitor): First-line agent for ovulation induction in PCOS (demonstrates higher live birth and ovulation rates compared to Clomiphene).

• Clomiphene Citrate (SERM): Alternative second-line agent for ovulation induction.

• Exogenous Gonadotropins / Assisted Reproductive Technology (ART): Used if oral agents fail, with careful monitoring to avoid Ovarian Hyperstimulation Syndrome (OHSS).

 

Red Flag Symptoms (When to Seek Urgent Evaluation)

​

• Abnormally Heavy or Prolonged Uterine Bleeding: Soaking through two or more pads/tampons an hour for consecutive hours (risk of severe anemia or underlying endometrial pathology).

• Severe, Unilateral Pelvic Pain: May indicate ovarian torsion (especially in ovaries enlarged by multiple follicles) or a ruptured ovarian cyst.

• Symptoms of Severe Obstructive Sleep Apnea: Loud snoring, gasping for air during sleep, or excessive daytime somnolence.

• Signs of Acute Metabolic Decompensation: Polydipsia, polyuria, unexplained weight loss, or lethargy (warranting immediate evaluation for Type 2 Diabetes).

​

                                                            References & Guidelines

​

• Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility. 2023.

• International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Monash University; 2023.

• American Society for Reproductive Medicine (ASRM). Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS.

• International Evidence-Based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (PMOS). Updated 2026.

​